You may have a point though. Although I still think PD-L1 will still be used, with the FDA approval of Keytruda, the reimbursement rates of this expensive treatment no longer hinges on PD-L1 testing because it is now a complementary test instead of a companion test. So, testing it could either stabilize or possibly decrease, but such changes probably won't become evident for another few years. Not sure what the future holds...